Form 8-K - Current report:
SEC Accession No. 0001193125-25-079656
Filing Date
2025-04-14
Accepted
2025-04-14 08:16:40
Documents
17
Period of Report
2025-04-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d857709d8k.htm   iXBRL 8-K 35862
2 EX-99.1 d857709dex991.htm EX-99.1 24937
3 EX-99.2 d857709dex992.htm EX-99.2 69626
4 EX-99.3 d857709dex993.htm EX-99.3 7547
8 GRAPHIC g857709g0414013521026.jpg GRAPHIC 2957
  Complete submission text file 0001193125-25-079656.txt   304174

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ikt-20250411.xsd EX-101.SCH 2857
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20250411_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20250411_pre.xml EX-101.PRE 11713
19 EXTRACTED XBRL INSTANCE DOCUMENT d857709d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 25834264
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)